{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:23:24Z","timestamp":1763389404690,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"am","delay-in-days":447,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jos.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T01:35:35Z","timestamp":1609205735000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin"],"prefix":"10.1016","volume":"27","author":[{"given":"Hiroshi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotake","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masachika","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jos.2020.11.006_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jos.2020.11.006_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jos.2020.11.006_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jso.24112","article-title":"The role of margins in extremity soft tissue sarcoma","volume":"113","author":"Byerly","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.jos.2020.11.006_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","article-title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis","volume":"17","author":"Callegaro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9829","key":"10.1016\/j.jos.2020.11.006_bib5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"10028","key":"10.1016\/j.jos.2020.11.006_bib6","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jos.2020.11.006_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jos.2020.11.006_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","author":"Demetri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.jos.2020.11.006_bib9","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","article-title":"Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent","volume":"21","author":"Dybdal-Hargreaves","year":"2015","journal-title":"Clin Canc Res"},{"issue":"10","key":"10.1016\/j.jos.2020.11.006_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Canc Sci"},{"issue":"6","key":"10.1016\/j.jos.2020.11.006_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial\u2013mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Canc"},{"key":"10.1016\/j.jos.2020.11.006_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.12.018","article-title":"Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: translational results of the EORTC 62052 trial","volume":"75","author":"Wiemer","year":"2017","journal-title":"Eur J Canc"},{"issue":"3","key":"10.1016\/j.jos.2020.11.006_bib13","first-page":"223","article-title":"Systemic inflammation, nutritional status and survival in patients with cancer","volume":"12","author":"McMillan","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"6024","key":"10.1016\/j.jos.2020.11.006_bib14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jos.2020.11.006_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","article-title":"The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review","volume":"132","author":"Dolan","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jos.2020.11.006_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","article-title":"Platelet-to-lymphocyte ratio in advanced Cancer: review and meta-analysis","volume":"483","author":"Li","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"22","key":"10.1016\/j.jos.2020.11.006_bib17","doi-asserted-by":"crossref","first-page":"31926","DOI":"10.18632\/oncotarget.7876","article-title":"Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.jos.2020.11.006_bib18","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.30057","article-title":"A\u00a0novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jos.2020.11.006_bib19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/01635581.2017.1367947","article-title":"Clinical value of nutritional status in cancer: what is its impact and how it affects disease progression and prognosis?","volume":"69","author":"Mantzorou","year":"2017","journal-title":"Nutr Canc"},{"issue":"11","key":"10.1016\/j.jos.2020.11.006_bib20","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.18632\/oncotarget.3283","article-title":"Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jos.2020.11.006_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjsurg.2014.10.021","article-title":"The derived neutrophil\/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients","volume":"210","author":"Szkandera","year":"2015","journal-title":"Am J Surg"},{"key":"10.1016\/j.jos.2020.11.006_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12885-015-1654-6","article-title":"Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma","volume":"15","author":"Que","year":"2015","journal-title":"BMC Canc"},{"issue":"2","key":"10.1016\/j.jos.2020.11.006_bib23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10147-017-1199-6","article-title":"Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma","volume":"23","author":"Kobayashi","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jos.2020.11.006_bib24","first-page":"400","article-title":"Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel","volume":"18","author":"Miyagawa","year":"2018","journal-title":"Clin Breast Canc"},{"issue":"9769","key":"10.1016\/j.jos.2020.11.006_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jos.2020.11.006_bib26","first-page":"909","article-title":"Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis","volume":"11","author":"Chen","year":"2019","journal-title":"Canc Manag Res"},{"key":"10.1016\/j.jos.2020.11.006_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.intimp.2018.10.002","article-title":"A\u00a0novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma","volume":"65","author":"Geng","year":"2018","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.jos.2020.11.006_bib28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3389\/fonc.2020.00766","article-title":"A\u00a0novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients","volume":"10","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.jos.2020.11.006_bib29","doi-asserted-by":"crossref","first-page":"E507","DOI":"10.1111\/ans.15480","article-title":"Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study","volume":"89","author":"Li","year":"2019","journal-title":"ANZ J Surg"},{"issue":"21","key":"10.1016\/j.jos.2020.11.006_bib30","doi-asserted-by":"crossref","first-page":"34954","DOI":"10.18632\/oncotarget.16865","article-title":"Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jos.2020.11.006_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jos.2020.11.006_bib32","first-page":"2929","article-title":"Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer","volume":"38","author":"Goto","year":"2018","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.jos.2020.11.006_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000876","article-title":"Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study","volume":"5","author":"Garrone","year":"2020","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.jos.2020.11.006_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/B:AGEN.0000029415.62384.ba","article-title":"Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor","volume":"6","author":"Kusumanto","year":"2003","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jos.2020.11.006_bib35","doi-asserted-by":"crossref","first-page":"9624760","DOI":"10.1155\/2017\/9624760","article-title":"Macrophages as key drivers of cancer progression and metastasis","volume":"2017","author":"Nielsen","year":"2017","journal-title":"Mediat Inflamm"},{"issue":"8","key":"10.1016\/j.jos.2020.11.006_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.jos.2020.11.006_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pan.2019.12.010","article-title":"A\u00a0systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer","volume":"20","author":"Pacheco-Barcia","year":"2020","journal-title":"Pancreatology"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265820303468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265820303468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:33:07Z","timestamp":1760556787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265820303468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0949265820303468"],"URL":"https:\/\/doi.org\/10.1016\/j.jos.2020.11.006","relation":{},"ISSN":["0949-2658"],"issn-type":[{"type":"print","value":"0949-2658"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jos.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of The Japanese Orthopaedic Association.","name":"copyright","label":"Copyright"}]}}